Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
CancerPublished 1 January 2001
Francis J. Giles, H. Kantarjian, Steve Kornblau, Deborah A. Thomas, Guillermo Garcia‐Manero, Tracey A. Waddelow
Citations280
SJR quartileQ1
SJR score2.95
SNIP1.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Hepatic venoocclusive disease (VOD) has been reported in patients who have undergone stem cell transplantation (SCT) after Mylotarg therapy and outside of the SCT setting, VOD has been associated very rarely with cytotoxic therapy.
Abstract
Mylotarg was shown to be associated with the development of potentially fatal VOD in patients with leukemia who had not received SCT. VOD occurred when Mylotarg was used either as a single agent or when it was given with other cytotoxic agents. VOD occurred in Mylotarg-treated patients who had received no prior cytotoxic therapy. The current study concluded that risk factors for VOD should be assessed when considering Mylotarg therapy, and that attempts to avoid and treat VOD are warranted in patients who receive Mylotarg therapy.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
HepatogastroenterologyHepatogastroenterology
2,449 Citations2011Yan Li, Ying Yang +2 more
The combined of CEA, CA19-9 and CA72.4 had 62.0% sensitivity in the diagnosis of recurrence after radical surgery, and patients whose tumor markers continue to increase should be highly suspected for relapse.
Annals of Internal MedicineVeno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients
1,192 Citations1993George B. McDonald, Mary S. Hinds +7 more
The clinical impression is that the current incidence of VOD at the institution is much higher than the 21% rate reported 9 years ago and that more patients have severe liver disease, which may explain the apparent increased incidence and severity of this complication.
TransplantationVENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION
908 Citations1987Richard J. Jones, KAMTHORN S. K. LEE +8 more
VOD is a common complication of bone marrow transplantation and has a specific clinical presentation, which usually allows diagnosis without the need of liver biopsy, and is the third leading cause of death in allogeneic graft recipients, and the second leading cause in patients receiving autologous transplants.
HepatologyVenocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors
852 Citations1984George B. McDonald, Pankaj Sharma +3 more
Hepatitis in this setting is probably of non‐A, non‐B viral etiology and represents a relative contraindication to marrow transplantation because of enhanced toxicity from conditioning chemoradiotherapy.
ScienceCalicheamicin γ <sub>1</sub> <sup>I</sup> : an Antitumor Antibiotic That Cleaves Double-Stranded DNA Site Specifically
566 Citations1988Nada Zein, A M Sinha +2 more
It is proposed that the observed cleavage specificity is a result of a unique fit of the drug and DNA followed by the generation of a nondiffusible 1,4-dehydrobenzene--diradical species that initiates oxidative strand scission by hydrogen abstraction on the deoxyribose ring.
BloodThe syndrome of hepatic veno-occlusive disease after marrow transplantation
476 Citations1995SI Bearman
Therapeutic drug monitoring of busulfan and pharmacokinetic dose adjustments appear to be useful in reducing the incidence of VOD in patients receiving this agent and treatment with recombinant tissue plasminogen activator has promise.
BloodSelective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
456 Citations1999Eric L. Sievers, F R Appelbaum +7 more
BloodSelective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
439 Citations1999Eric L. Sievers, Frederick R. Appelbaum +7 more
BloodTargeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
338 Citations2001Vincent H. J. van der Velden, Jeroen G. te Marvelde +5 more
Data indicate that Mylotarg is rapidly and specifically targeted to CD33(+) cells, followed by internalization and subsequent induction of cell death, which is a promising therapy in patients with acute myeloid leukemia.
Journal of Clinical OncologyVenoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.
256 Citations1993Scott I. Bearman, Garnet L. Anderson +4 more
The course of VOD after cytoreductive therapy can be predicted by knowing the serum bilirubin and weight gained within 1 to 2 weeks of transplantation, and probability estimates derived from patient data are highly specific and moderately sensitive.
PubMedPreparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.
238 Citations1993Lois M. Hinman, Philip R. Hamann +4 more
Annals of Internal MedicineUrsodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation
190 Citations1998James Essell, Mark T. Schroeder +8 more
A randomized, double-blind, placebo-controlled study to confirm the reduction in hepatic complications seen with ursodiol prophylaxis in a pilot trial of veno-occlusive disease.
British Journal of HaematologyDefibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study
183 Citations2000Rajesh Chopra, J.D. Eaton +10 more
It is demonstrated that DF is an active treatment for VOD following SCT and a randomized trial is now underway in order to further evaluate its role.
PubMedMolecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
160 Citations2000Joseph G. Jurcic, Tony DeBlasio +3 more
It is suggested that HuM195 has activity against minimal residual disease in APL, particularly in newly diagnosed patients, as well as similar patients treated on earlier studies.
The Journal of Clinical PharmacologyPharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse
156 Citations2001James A. Dowell, Joan Korth‐Bradley +3 more
The pharmacokinetics of gemtuzumab ozogamicin has been characterized in AML patients receiving doses at the proposed therapeutic level and no relationship was found between plasma concentration and response at the recommended dose.
TransplantationTHE CLINICAL COURSE OF 53 PATIENTS WITH VENOCCLUSIVE DISEASE OF THE LIVER AFTER MARROW TRANSPLANTATION
156 Citations1985George B. McDonald, Pankaj Sharma +3 more
Patients with serious VOD had significantly higher maximal values for bilirubin and SGOT, gained more weight, and were more likely to have encephalopathy, and supportive treatment did not appear to influence the outcome.
HepatologySupport of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat
134 Citations2000Xiangdong Wang, Gary C. Kanel +1 more
Intraportal infusion of GSH protects against monocrotaline toxicity, at least partially by maintaining sinusoidal endothelial cell GSH levels and protected against histological and clinical evidence of HVOD.
Annals of Internal MedicineVeno-Occlusive Disease of the Liver After Chemotherapy of Acute Leukemia
133 Citations1976Paul F. Griner, AHMAD ELBADAWI +1 more
Although 6-thioguanine was most likely responsible for this syndrome, it is not possible to eliminate cytosine arabinoside as the causative agent, so physicians should be aware of this possible complication.
British Journal of HaematologyDefibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study
128 Citations2000Rajesh Chopra, J.D. Eaton +10 more
PubMedSupersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
111 Citations1998Philip Caron, Larry J. Dumont +1 more
These studies suggest that high doses of HuM195 achieve a long serum half-life, with tolerable toxicity and without immunogenicity, and one patient with acute myelogenous leukemia achieved a complete remission, lasting > 32 months, at the first dose level.
LeukemiaMonoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
103 Citations2000ID Bernstein
Response rates of acute myelogenous leukemia patients treated with the newly developed anti-CD33 antibody-calicheamicin conjugate suggest that at least for a proportion of patients early precursors responsible for re-establishing hematopoiesis are likely to be predominantly normal in origin.
BiochemistryExclusive production of bistranded DNA damage by calicheamicin
92 Citations1993Peter C. Dedon, Aaron Salzberg +1 more
Three model DNA systems revealed three important features of the bistranded damage produced by CAL, including a major lesion consisting of an abasic site on one strand and a direct strand break on the other that is consistent with an intermediate in the partitioning that is dependent on bistRanded lesions.
Annals of Internal MedicineHepatic Veno-Occlusive Disease Caused by 6-Thioguanine
82 Citations1982Robert A. Gill, GERALD R. ONSTAD +3 more
This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno/occlusive related solely to 6-thioguanine.
Journal of Clinical OncologyHepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.
73 Citations1990Lois Ayash, M Hunt +8 more
Journal of Molecular BiologySolution structure of the calicheamicin γ1-DNA complex
73 Citations1997Rupesh Kumar, Norihiro Ikemoto +1 more
The refined solution structures of the calicheamicin gamma 1I-DNA hairpin duplex complex provide a molecular explanation of the sequence specificity of binding and cleavage by this member of the enediyne family of antitumor antibiotics.
Current Opinion in OncologyVeno-occlusive disease of the liver
63 Citations2000Scott I. Bearman
A better understanding of the pathogenesis of VOD will lead to more effective prevention and treatment strategies, and no pharmacologic approaches that clearly prevent or treat VOD have been identified.
Immunology and Cell BiologyDifferential expression of surface antigens on activated endothelium
61 Citations1993Emmanuel J. Favaloro
Assessment of potential changes to the endothelial cell surface using a large number of previously untested monoclonal antibodies, and the cytokines TNF‐α and γ‐IFN, as well as the proteolytic enzyme thrombin finds no consistency in reactivity patterns.
CancerVenoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma
61 Citations1997José Antonio Ortega, Sarah S. Donaldson +3 more
The authors report the unusual and unexpected complication of VOD of the liver occurring in children with rhabdomyosarcoma who were receiving vincristine, actinomycin D, and cyclophosphamide according to the chemotherapy regimens of the Intergroup RhabdomYosarComa Study (IRS) IV.
PubMedPilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
55 Citations1992James Essell, James Thompson +5 more
The data suggest that ursodiol may increase the incidence of VOD in allogeneic BMT patients and decrease the severity of veno-occlusive disease of the liver following allogeneics bone marrow transplantation (BMT).
PubMedAntibody-targeted therapy for myeloid leukemia.
53 Citations1999Appelbaum Fr
Initial in vivo studies with an unmodified murine anti-CD33 antibody in patients with AML demonstrated that the antibody quickly bound to leukemia cells and that the antigen-antibody complex rapidly internalized following cell binding, however, when administered to patients with overt leukemia, unmodified antibody resulted in only brief decreases in peripheral blast counts, not in sustained response.
PubMedTargeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma.
51 Citations1998Holger N. Lode, R. Reisfeld +4 more
The first successful use of calicheamicin theta(I)1 for targeted chemotherapy in a clinically relevant syngeneic metastasis model is described, demonstrating effective suppression of hepatic metastases.
PubMedA phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
50 Citations1999Steven E. Kossman, David A. Scheinberg +3 more
Whether low-dose IL-2 could safely enhance the numbers of NK cells and therefore the cytotoxic capability of HuM195 via presumptive NK cell antibody-dependent cellular cytotoxicity in vivo against myeloid leukemia cells is sought.
Journal of Clinical Pathology6-Thioguanine as a cause of toxic veno-occlusive disease of the liver
48 Citations1982M. H. Satti, K. Weinbren +1 more
Treatment included administration of 6-thioguanine which was the only relevant compound used in the first patient and which was combined with cytosine arabinoside in the second patient.
PubMedInduction of hepatic veno-occlusive disease in dogs.
47 Citations1987Howard M. Shulman, K.H. Luk +3 more
The authors attempted to induce hepatic veno-occlusive disease in 64 dogs and found that VOD can be produced in dogs especially with monocrotaline or BSO given before and L-PAM +/- irradiation.
Annals of OncologyPhase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer
41 Citations2000AM Gillespie, T Broadhead +5 more
European RadiologyMR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation
40 Citations2000Maurice A. A. J. van den Bosch, L. Van Hoe
It is concluded that the use of MRI as a complementary technique following non-conclusive US examination enabled a timely diagnosis of this life-threatening disease in both patients.
British Journal of RadiologyAcute radiation-induced hepatic injury: evaluation by triphasic contrast enhanced helical CT.
37 Citations2000Sylvie Willemart, N Nicaise +2 more
A case of radiation-induced hepatic injury as a complication of localized abdominal radiotherapy for epidural spread of non-Hodgkin's lymphoma and changes typical of veno-occlusive disease are reported.
CancerVeno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia
37 Citations1983Cyril D’Cruz, Robert S. Wimmer +3 more
Three children developed acute veno‐occlusive disease of the liver following combination chemotherapy for acute myelocytic leukemia, with acute onset of hepatomegaly and thrombocytopenia in the absence of significant transaminasemia or icterus.
Journal of Biological ChemistryEnediyne-mediated DNA damage in nuclei is modulated at the level of the nucleosome.
34 Citations1994Liang Yu, I. Goldberg +1 more
DNA damage in HeLa nuclei and isolated nucleosome core particles has been examined for several members of the enediyne family of antitumor antibiotics and is shown to be caused directly by the drugs with little contribution from endogenous factors, such as nucleases and topoisomerases.
Cancer Biotherapy and RadiopharmaceuticalsAntibody Therapy of Acute Myelogenous Leukemia
23 Citations2000Joseph G. Jurcic
A genetically engineered, humanized anti-CD33 antibody HuM195 has demonstrated activity against over relapsed acute myelogenous leukemia (AML) and against minimal residual disease in acute promyelocytic leukemia (APL).
Proceedings of the National Academy of SciencesSupercoiling affects the accessibility of glutathione to DNA-bound molecules: Positive supercoiling inhibits calicheamicin-induced DNA damage
23 Citations1998William A. LaMarr, Liang Yu +2 more
The results suggest that supercoiling may affect both the activity of nonintercalating genotoxins in vivo and the accessibility of glutathione and other small physiologic molecules to DNA-bound chemicals or reactions occurring in the grooves of DNA.
BiochemistryDNA Bending Is a Determinant of Calicheamicin Target Recognition
21 Citations2000Aaron Salzberg, Peter C. Dedon
Results are consistent with DNA bending as part of an induced-fit mechanism of DNA target recognition and with the hypothesis that the preferred targets of calicheamicin, the 3' ends of oligopurine tracts, are characterized by unique conformational properties.
Pediatric Hematology and OncologyVeno-Occlusive Disease-Like Hepatotoxicity in two Children Receiving Chemotherapy for Wilms' Tumor and Clear Cell Sarcoma of Kidney
15 Citations1998Volkan Hazar, Tezer Kutluk +4 more
It is concluded that vincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.
Investigational New DrugsPhase I Study of Irofulven (MGI 114), an Acylfulvene Illudin Analog, in Patients with Acute Leukemia
15 Citations2001Francis J. Giles, Jörge E. Cortes +6 more
Proposed phase II studies will further define the activity of Irofulven in patients with better prognosis AML and in otherhematological malignancies, both as a single agent and incombination regimens, particularly with topoisomerase 1inhibitors.
Bone Marrow TransplantationColor-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment
14 Citations1998Pieter Sonneveld, JS Laméris +3 more
It is demonstrated that color-flow sonography can be used to confirm the clinical diagnosis of VOD in a patient with acute myeloid leukemia, and this technique provides a way for easily and reliably evaluating the effect in relation to dose of thrombolytic therapy needed.
PathologyActinomycin D associated hepatic veno-occlusive disease — A report of 2 cases
12 Citations1994Karen L. Barclay, Mee Ling Yeong
The pathological changes in liver biopsy samples taken from 2 children who developed liver failure after combined chemotherapy for Wilms' tumor were those of nodular hyperplasia, sclerosis of terminal hepatic venules with associated zone 3 hemorrhagic necrosis, and sinusoidal fibrosis.
PubMedPathophysiological aspects of dacarbazine-induced human liver damage.
10 Citations1985Ralf Paschke, M Heine
It is suggested that peripheral eosinophilia, so far interpreted as a sign of an allergic reaction induced by Dacarbazine, can be observed together with obvious signs of toxic drug reaction, thus providing further evidence of a toxic mechanism of Dacbazine-induced VOD or BCS.
Bioorganic & Medicinal ChemistryRegulation of apoptosis in leukemic cells by analogs of dynemicin A
9 Citations1994Andrew Hiatt, Robert A. Merlock +2 more
It was found that the induction of apoptosis and nuclear degradation by the synthetic compounds did not require an ability to bind or cleave DNA and preventive capability of the stabilized analogs was observed against a wide variety of toxic agents including topoisomerase I and II inhibitors, anti-mitotic and DNA anti-metabolite drugs, as well as alkylating agents.
Pediatric Hematology and OncologyVENO-OCCLUSIVE DISEASE OF THE LIVER ASSOCIATED WITH THIOPURINES IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA
9 Citations2000José Merino, Francesco Casanova +3 more
A 4-year-old boy was admitted for ascites, edemas, oliguria, weight gain, and gingivorrhage, and surreptitious ingestion of an herbal remedy (Silybum marianum) was referred by the mother during VOD.
Clinical Nuclear MedicineGrossly Abnormal Liver-Spleen Scan in a Patient with Veno-occlusive Disease of the Liver that Normalized Completely on Follow-up
2 Citations1993Mukesh J. Joshi, Patrick V. Ford +2 more
In the case, the gross abnormality of liver parenchyma, ascites, and colloid shift to spleen, bones, and lungs found on a Tc-99m SC liver-spleen scan, and confirmed on liver biopsy, resolved completely on follow-up.